Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Aarey Drugs & Pharmaceuticals Limited specializes in the production of generic pharmaceuticals, primarily serving the Indian market with a growing export segment to emerging economies. The company differentiates itself through a robust pipeline of affordable medications and a focus on regulatory compliance, which enhances its competitive positioning in a price-sensitive market.
Aarey generates revenue primarily through the sale of generic drugs, leveraging its cost-efficient production processes and economies of scale. The company benefits from a strong regulatory framework that allows it to maintain pricing power in a competitive landscape, particularly in the Indian market.
Regulatory approvals for new generic drugs
Changes in pricing policies in the Indian pharmaceutical market
Export growth to emerging markets
Cost fluctuations in raw materials
Regulatory changes impacting pricing and market access
Technological disruption in drug manufacturing processes
Intensifying competition from both local and international generic manufacturers
Potential for price erosion in key therapeutic areas
Low net margins (1.2%) indicate limited financial flexibility
Potential liquidity issues due to negative free cash flow
moderate - The pharmaceutical industry is somewhat insulated from economic cycles, but consumer spending on healthcare can be affected by broader economic conditions.
Rising interest rates could increase financing costs for Aarey, impacting its capital expenditures and potentially leading to reduced investment in growth initiatives.
minimal - Aarey maintains a conservative debt profile with a debt/equity ratio of 0.33, reducing reliance on credit markets.
value - Investors may be drawn to Aarey due to its low price-to-sales ratio (0.5x) and potential for recovery in profitability.
moderate - The stock has shown significant returns over the past year (75.7%), indicating some volatility.
